Parenteral pentavalent antimonials remain the standard therapy for cutaneous leishmaniasis. More effective and patient-compliant topical treatments are an important alternative treatment for the localized self-limiting forms of this disease. Two paromomycin ointments are commercially available but their use is limited by either toxicity or lack of efficacy. Other topical formulations have been in clinical trials, but many results have been equivocal and no major breakthroughs have been achieved. The focus of this review is on recent developments in the field of topical treatment for cutaneous leishmaniasis and rational approaches to enhance topical drug absorption
Cutaneous leishmaniasis (CL) is a disfiguring disease that confronts clinicians with a quandary: lea...
Cutaneous leishmaniasis (CL) is treated with painful intralesional injections of meglumine antimonia...
Because topical therapy is easy and usually painless, it is an attractive first-line option for the ...
Cutaneous leishmaniasis has been endemic since decades. Millions of cases are reported worldwide spe...
Cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (ML) show clinical spectra that can ran...
Abstract. A double-blind, randomized trial was undertaken in Guatemala to determine the therapeutic ...
BackgroundParomomycin-based topical treatments were shown to be effective in curing cutaneous leishm...
Studies on in vitro skin permeation and in vivo anti-leishmanial activity in mice experimentally inf...
Sixty-seven patients, 19 females and 48 males, 4-66 years old, suffering from lesions of cutaneous l...
Diagnosis and therapy of cutaneous leishmaniasis (CL) can be difficult due to the variability of the...
The first choice drugs for the treatment of cutaneous and mucocutaneous leishmaniasis are pentavalen...
Leishmania parasites are the etiological agents of Leishmaniasis, a tropical disease that affects ar...
AbstractThere have been many treatment modalities used for the therapy of cutaneous leishmaniasis. A...
High cost, poor compliance, and systemic toxicity have limited the use of pentavalent antimony compo...
Leishmania major (L. major) causes cutaneous leishmaniasis in the Old World. The infection mostly in...
Cutaneous leishmaniasis (CL) is a disfiguring disease that confronts clinicians with a quandary: lea...
Cutaneous leishmaniasis (CL) is treated with painful intralesional injections of meglumine antimonia...
Because topical therapy is easy and usually painless, it is an attractive first-line option for the ...
Cutaneous leishmaniasis has been endemic since decades. Millions of cases are reported worldwide spe...
Cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (ML) show clinical spectra that can ran...
Abstract. A double-blind, randomized trial was undertaken in Guatemala to determine the therapeutic ...
BackgroundParomomycin-based topical treatments were shown to be effective in curing cutaneous leishm...
Studies on in vitro skin permeation and in vivo anti-leishmanial activity in mice experimentally inf...
Sixty-seven patients, 19 females and 48 males, 4-66 years old, suffering from lesions of cutaneous l...
Diagnosis and therapy of cutaneous leishmaniasis (CL) can be difficult due to the variability of the...
The first choice drugs for the treatment of cutaneous and mucocutaneous leishmaniasis are pentavalen...
Leishmania parasites are the etiological agents of Leishmaniasis, a tropical disease that affects ar...
AbstractThere have been many treatment modalities used for the therapy of cutaneous leishmaniasis. A...
High cost, poor compliance, and systemic toxicity have limited the use of pentavalent antimony compo...
Leishmania major (L. major) causes cutaneous leishmaniasis in the Old World. The infection mostly in...
Cutaneous leishmaniasis (CL) is a disfiguring disease that confronts clinicians with a quandary: lea...
Cutaneous leishmaniasis (CL) is treated with painful intralesional injections of meglumine antimonia...
Because topical therapy is easy and usually painless, it is an attractive first-line option for the ...